Convalescent plasma therapy in COVID-19 patients: a non-randomized case-control study with concurrent control

Area of Science:

• Medical research
• Infectious diseases
• Hematology

Background:

• Convalescent plasma therapy (CPT) has been explored as a treatment for COVID-19.
• Previous studies on CPT for COVID-19 have yielded conflicting results.
• The efficacy of CPT in reducing mortality and ICU admission in COVID-19 patients requires further clarification.

Purpose of the Study:

• To evaluate the effectiveness of convalescent plasma therapy in reducing in-hospital mortality and ICU admission among COVID-19 patients.
• To compare outcomes of COVID-19 patients treated with convalescent plasma versus those who did not receive it.

Main Methods:

• A non-randomized case-control study was conducted with contemporaneous controls.
• Patients receiving convalescent plasma were compared to those who did not, both hospitalized with COVID-19.
• Primary outcomes assessed were ICU admission and in-hospital death.

Main Results:

• Patients treated with convalescent plasma exhibited significantly lower in-hospital mortality compared to the control group (RR 0.48; 95% CI: 0.29 to 0.79).
• No significant difference was observed in ICU admission rates between the convalescent plasma group and the control group (RR 0.80; 95% CI: 0.47 to 1.35).
• The observed reduction in mortality remained consistent across different control group subsets.

Conclusions:

• Convalescent plasma therapy may be associated with reduced in-hospital mortality in COVID-19 patients.
• The study suggests a potential benefit of CPT in decreasing mortality, but not necessarily ICU admission.
• Further prospective studies are recommended to confirm these findings due to the retrospective nature of this investigation.